[
    [
        {
            "time": "2023-10-05",
            "original_text": "Low Forward Price-Earnings Ratio Stock Picks",
            "features": {
                "keywords": [
                    "Price-Earnings",
                    "Ratio",
                    "Stock",
                    "Picks"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Low Forward Price-Earnings Ratio Stock Picks",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Pharma Stock Roundup: ABBV's Positive Skyrizi Data, AZN, PFE, RHHBY's FDA Updates",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "ABBV",
                    "Skyrizi",
                    "Positive",
                    "Data",
                    "AZN",
                    "PFE",
                    "RHHBY",
                    "FDA",
                    "Updates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: ABBV's Positive Skyrizi Data, AZN, PFE, RHHBY's FDA Updates",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies",
            "features": {
                "keywords": [
                    "AbbVie",
                    "ABBV",
                    "Skyrizi",
                    "Succeeds",
                    "Crohn's",
                    "Disease",
                    "Studies"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]